Intrinsic Bioprobes Enters into a $1.27M Contract with the National Cancer Institute to Develop Multiplex Mass Spectrometric Immunoassays for Detection of Low Abundance Cancer Related Proteins
News Apr 01, 2009
The total cost of the two and a half years contract is $1,276,360, out of which $1,130,272 is Federal money provided by the NCI, and $146,088 is the contractor’s share provided by Intrinsic Bioprobes Inc. This contract is in support of NCI’s Clinical Proteomic Technologies for Cancer initiative to assess and apply proteomic technologies and data resources to solve critical problems in cancer research (http://proteomics.cancer.gov).
“The purpose of this contract is to stimulate the development of multiplex mass
spectrometric immunoassay for the detection of low abundance cancer related
proteins/peptides from bodily fluids” says Dobrin Nedelkov, Ph.D., the Scientific Director of Intrinsic Bioprobes. “The application of proteomics tools in clinical setting lags far behind their use in basic science and drug discovery. The multiplex mass spectrometric immunoassays will bridge that gap because they are highly specific and selective, have ultra-sensitive detection capabilities and broad dynamic range, and require limited sample preparation. The mass spectrometric aspect of the assays also enables singlestep detection of protein isoforms and their individual quantification, which is an important protein diversity aspect regularly overlooked in contemporary proteomics
approaches”, adds Nedelkov.